A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

ClinicalTrials.gov ID: NCT01889186

Public ClinicalTrials.gov record NCT01889186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Study identification

NCT ID: NCT01889186
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: AbbVie; Industry
Enrollment: 158 participants

Conditions and interventions

Conditions

Interventions

ABT-199 (Main Cohort) Drug
ABT-199 (Safety Expansion Cohort) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 26, 2013
Primary completion: Oct 27, 2020
Completion: Dec 14, 2020
Last update posted: Dec 15, 2021

2013 – 2020

United States locations

U.S. sites: 16
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center - North Campus /ID# 96748	Tucson	Arizona	85719-1478	—
City of Hope /ID# 112875	Duarte	California	91010	—
Moore UC San Diego Cancer Center /ID# 91793	La Jolla	California	92093	—
Stanford University School of Med /ID# 105117	Stanford	California	94305-2200	—
Georgetown University Hospital /ID# 96954	Washington D.C.	District of Columbia	20007	—
Northwestern University Feinberg School of Medicine /ID# 92499	Chicago	Illinois	60611-2927	—
The University of Chicago Medical Center /ID# 96960	Chicago	Illinois	60637-1443	—
Ingalls Memorial Hosp /ID# 92497	Harvey	Illinois	60426	—
Dana-Farber Cancer Institute /ID# 92494	Boston	Massachusetts	02215	—
Henry Ford Health System /ID# 97795	Detroit	Michigan	48202	—
Hackensack Univ Med Ctr /ID# 92500	Hackensack	New Jersey	07601	—
Rutgers Cancer Institute of New Jersey /ID# 92513	New Brunswick	New Jersey	08903	—
Columbia Univ Medical Center /ID# 103835	New York	New York	10032-3725	—
Columbia Univ Medical Center /ID# 94716	New York	New York	10032-3725	—
Cleveland Clinic Main Campus /ID# 92495	Cleveland	Ohio	44195	—
University of Texas MD Anderson Cancer Center /ID# 92521	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01889186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 15, 2021 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01889186 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →